Ionis Pharmaceuticals (IONS) Free Cash Flow (2009 - 2026)

Ionis Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at -$814.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 398.67% year-over-year to -$814.6 million in Q1 2026; TTM through Mar 2026 was -$920.3 million, a 65.77% decrease from a year earlier, with the FY2025 full-year figure at -$269.1 million, up 50.74% from the prior year.
• Free Cash Flow fell to -$814.6 million in Q1 2026 per IONS's latest filing, from -$108.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $139.0 million in Q2 2025 and bottomed at -$814.6 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$124.0 million (2024), against an average of -$132.4 million.
• Across the five-year window, Free Cash Flow plunged 520.48% in 2024 and surged 210.24% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$204.3 million in 2022, then soared by 116.48% to $33.7 million in 2023, then plunged by 520.48% to -$141.6 million in 2024, then rose by 23.72% to -$108.0 million in 2025, then sank by 654.0% to -$814.6 million in 2026.
• Per Business Quant, the three latest IONS Free Cash Flow figures stand at -$814.6 million (Q1 2026), -$108.0 million (Q4 2025), and -$136.7 million (Q3 2025).